ICT03 Es5Alternative Names: Es5; ICT03-Es5
Latest Information Update: 28 Jul 2016
At a glance
- Originator University of Salford
- Developer Incanthera
- Mechanism of Action DNA cross linking agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Liver cancer; Non-small cell lung cancer